Harrow, Inc. $HROW Shares Bought by Sei Investments Co.

Sei Investments Co. raised its holdings in Harrow, Inc. (NASDAQ:HROW) by 119.5% during the 1st quarter, Holdings Channel.com reports. The firm owned 38,032 shares of the company’s stock after acquiring an additional 20,706 shares during the period. Sei Investments Co.’s holdings in Harrow were worth $1,341,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Harrow in the fourth quarter worth about $26,000. KBC Group NV purchased a new position in Harrow during the first quarter valued at approximately $31,000. Raymond James Financial Inc. acquired a new position in Harrow in the second quarter valued at approximately $48,000. SBI Securities Co. Ltd. lifted its holdings in Harrow by 393.5% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock valued at $52,000 after acquiring an additional 846 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Harrow by 25.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock worth $88,000 after purchasing an additional 369 shares in the last quarter. 72.76% of the stock is owned by institutional investors and hedge funds.

Harrow Stock Down 3.1%

Shares of HROW opened at $39.42 on Wednesday. The company has a current ratio of 2.48, a quick ratio of 2.30 and a debt-to-equity ratio of 10.30. Harrow, Inc. has a 12 month low of $28.54 and a 12 month high of $54.85. The stock’s 50 day moving average is $40.60 and its two-hundred day moving average is $39.96. The firm has a market cap of $1.47 billion, a P/E ratio of -39.42 and a beta of 0.28.

Harrow (NASDAQ:HROW) last announced its earnings results on Monday, August 10th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.16). Harrow had a negative return on equity of 31.83% and a negative net margin of 13.51%.The business had revenue of $70.66 million for the quarter, compared to analyst estimates of $69.84 million. Analysts predict that Harrow, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Harrow

In related news, CFO Andrew R. Boll purchased 3,500 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The stock was bought at an average price of $29.90 per share, with a total value of $104,650.00. Following the acquisition, the chief financial officer owned 814,679 shares in the company, valued at $24,358,902.10. The trade was a 0.43% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Adrienne L. Graves acquired 1,000 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were bought at an average cost of $31.07 per share, for a total transaction of $31,070.00. Following the completion of the acquisition, the director owned 1,000 shares of the company’s stock, valued at approximately $31,070. This represents a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 12.80% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on HROW shares. BTIG Research reaffirmed a “buy” rating and set a $63.00 price objective on shares of Harrow in a research note on Tuesday. Cantor Fitzgerald lowered their price target on shares of Harrow from $91.00 to $88.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Wall Street Zen lowered shares of Harrow from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a research report on Monday, July 20th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Harrow has a consensus rating of “Moderate Buy” and a consensus price target of $69.43.

Trending Headlines about Harrow

Here are the key news stories impacting Harrow this week:

• Positive Sentiment: Harrow reported second-quarter revenue of approximately $70.7 million, up 10.9% year over year and slightly above the $70.35 million analyst estimate. Gross profit increased 6% to $50.4 million. Harrow Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Management issued fiscal 2026 revenue guidance of $350 million to $365 million, above the roughly $348.8 million consensus forecast, suggesting confidence in continued commercial growth. Harrow earnings and guidance
• Positive Sentiment: BTIG reaffirmed its Buy rating and set a $63 price target, implying substantial upside from recent trading levels. The earnings call also emphasized record demand and strategic expansion. BTIG rating update
• Neutral Sentiment: The reported short-interest data showed zero shares and a zero-day days-to-cover ratio, but the stated month-over-month increase was listed as “NaN,” making the data unreliable and unlikely to provide a meaningful trading signal.
• Negative Sentiment: Harrow reported a quarterly loss of $0.34 per share, substantially worse than the $0.18 consensus estimate. Operating loss widened to $11.0 million, net loss attributable to common shareholders reached $17.3 million, and operating cash flow was negative $9.8 million. Harrow Q2 loss report
• Negative Sentiment: Profitability remains under pressure despite sales growth, while total liabilities rose to approximately $402 million. The earnings miss and heavier balance sheet appear to be the main reasons investors reacted negatively.

Harrow Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.